A rich source of innovation for the Ceva Group.
If there is one field in which Ceva Animal Health has demonstrated the full extent of its innovation capacities, it is that of companion animals.
Cat and dog behaviour
Through several major innovations, Ceva has opened up the possibility for vets to address behavioural disorders in cats and dogs, an area about which little was known until now and the subject of few clinical studies.
- 1996: Beginning of a new therapeutic approach: launch of FELIWAY® to treat behavioural disorders in cats
- 2000: Launch of D.A.P.® now ADAPTIL® providing an innovative approach to the behavioural problems that are specific to the species.
When we speak of locomotion in companion animals, the key problem is the degenerative joint disease - arthritis
that affects our cats and dogs as they live longer.
For these animals, CEVA has developed specialities that are widely recognised for their efficacy: anti-inflammatory drugs (PENTOSAN 100, SYNOVAN) or chondroprotectors (JOINT GUARD®).
The DentiPet range of specialist dental products is designed to provide easy-to-use effective solutions to common dental problems. The range includes: DentiPet Toothpaste (2 flavours), and DentiPet Fingerbrush.
We have animals covered when it comes to sun protection with:- Filta-Bac® an antibacterial sunscreen.
ENZYPLEX, a digestive enzyme supplement; and PEPTOSYL (Bismuth Salicylate), to aid in the treatment of gastroenteritis and diarrhoea in horses and dogs.
Other therapeutic fields
Central Nervous System (CNS), which includes Sedation and Anaesthesia: Sedamed™ (Medetomidine HCl); Tranquilisers: A.C.P. Injection (Acepromazine), A.C.P. Tablets (Acepromazine); Antiepileptics: Epibrom (Potassium Bromide); Antiemetics: Metomide Injection (Metoclopramide HCl).
Product lines are adapted to local demand and regulatory requirements from one country to another. For further information, please take a look at the CEVA site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.